99mTc-EDDA/HYNIC-TOC somatostatin receptor scintigraphy in daily clinical practice.
BACKGROUND
This study aimed to assess the impact of 99mTc-EDDA/HYNIC-TOC (99mTc-TOC) somatostatin receptor scintigraphy (SRS) in clinical practice.


METHODS
One hundred seventeen patients were divided into 6 groups: 1, initial detection and localization of suspected neuroendocrine tumor (NET); 2, tumor staging before therapy; 3, staging of NET of unknown origin, 4, restaging after surgery of primary tumor; 5, diagnosis of solitary pulmonary nodules (SPNs), and 6, follow-up after "cold" somatostatin analogues treatment.


RESULTS
In group 1, clinical suspicions were not confirmed in any of the patients; in group 2, most of the primary lesions showed overexpression of somatostatin receptors (SSRT); in group 3, the primary tumor was not identified in any of the patients; in group 4, recurrences were depicted in 7 out of 47 patients; in group 5, only 1 malignant SPN was detected, and in group 6, regression of primary mass and metastases were seen on follow-up SRS in 1 patient.


CONCLUSIONS
99mTc-TOC SRS is useful in staging of SSRT-overexpressing tumors of known and unknown primary origin, as well as in restaging after primary tumor surgery. This method is less effective in detecting suspected NET and assessing SPNs. Further investigation is necessary to evaluate the usefulness of SRS in monitoring patients after biological treatment.
Chrapko
Beata Ewa
BE
Chair and Department of Nuclear Medicine, Medical University of Lublin, 20-954 Lublin, Poland. beata.chrapko@wp.pl
Nocuń
Anna
A
Gołebiewska
Renata
R
Stefaniak
Bogusław
B
Korobowicz
Elzbieta
E
Czekajska-Chehab
Elzbieta
E
Sawicki
Marek
M
Polkowski
Wojciech Piotr
WP
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008495:Medical Oncology / Q000379:methods; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging / Q000379:methods; D009369:Neoplasms / Q000175:diagnosis / Q000473:pathology*; D018358:Neuroendocrine Tumors / Q000175:diagnosis* / Q000473:pathology; D015282:Octreotide / Q000031:analogs & derivatives* / Q000494:pharmacology; D015609:Organotechnetium Compounds / Q000494:pharmacology*; D011877:Radionuclide Imaging / Q000379:methods*; D017481:Receptors, Somatostatin / Q000378:metabolism*
D015609:Organotechnetium Compounds; D017481:Receptors, Somatostatin; C410263:technetium Tc 99m hydrazinonicotinyl-Tyr(3)-octreotide; D015282:Octreotide